Eli Lilly Agrees To Donate Insulin To Clinics Across Minnesota In Lawsuit Settlement
Minnesota Attorney General Keith Ellison announced Wednesday that pharmaceutical giant Eli Lilly will donate insulin to clinics around the state for the next five years—and keep a $35 price cap for...
Liver Disease Biotechs Dive on Eli Lilly Data
MASH is an advanced liver disorder that can lead to cancer or liver failure.
Eli Lilly settles Minnesota lawsuit over insulin pricing
Eli Lilly has settled a lawsuit by Minnesota that accused the three largest insulin makers of deceptively raising the price of insulin, which is used to treat diabetes.
Eli Lilly, Novo Nordisk Could Be First Trillion-Dollar Drug Stocks
The trillion-dollar market valuation club is currently dominated by the tech sector. Saudi Aramco is the sole exception.
Healthy Returns: Novo Nordisk, Eli Lilly are tackling weight loss drug supply woes
Novo Nordisk and Eli Lilly are working to increase supply of their popular weight loss drugs. Meanwhile, the implantable neurotechnology field is heating up.
Compared to Estimates, Lilly (LLY) Q4 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Lilly (LLY) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compar...
Eli Lilly says weight loss drug shows promise as treatment for fatty liver disease
The results add to a long list of potential health benefits of tirzepatide besides helping patients shed significant pounds and regulate blood sugar.
Eli Lilly (LLY) Q4 Earnings Beat, Mounjaro, Zepbound Drive Sales
Eli Lilly (LLY) beats fourth-quarter estimates for earnings as well as sales. The company issues an upbeat guidance for 2024.
Why Eli Lilly Stock Jumped as Much as 5.1% Today Then Gave Up Its Gains
Eli Lilly handily beat Wall Street estimates with its Q4 results. The midpoint of the company's full-year 2024 revenue guidance range also topped the average analysts' estimate.
Why Eli Lilly Deserves to Unseat Tesla Among the Magnificent 7
The pharmaceutical company's market cap has surpassed Tesla's, thanks to the rapid growth of its GLP-1 business.
Eli Lilly weight loss drugs are 'mega-growth assets' BMO's Evan Seigerman says
Eli Lilly (LLY) shares surged Tuesday morning, after the company reported strong fourth-quarter results driven by high demand for weight loss drug Zepbound and diabetes treatment Mounjaro. Evan Sei...
Eli Lilly hits record high: Here's what investors need to know
Jared Holz, Mizuho Securities healthcare strategist, joins 'Squawk on the Street' to discuss why supply imbalances could boost Eli Lilly's future earnings reports, if clients are asking about the c...
Eli Lilly buoyed by demand for new weight loss drug
Pharma giant Eli Lilly and Co said expects revenues to grow by 18% in 2024 to more than $40 billion with the surge is attributed to the growing demand for its diabetes and obesity treatments, Mounj...
Tesla Now Worth $110 Billion Less Than Weight Loss Drug Maker Eli Lilly
Out with electric vehicles, in with weight loss drugs: Investors have ditched one-time favorite Tesla for pharmaceutical giant Eli Lilly, as the early days of long-established Eli Lilly's diabetes ...
Eli Lilly (LLY) Tops Q4 Earnings and Revenue Estimates
Eli Lilly (LLY) came out with quarterly earnings of $2.49 per share, beating the Zacks Consensus Estimate of $2.47 per share. This compares to earnings of $2.09 per share a year ago.
Related Companies